PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast And Market Analysis to 2022

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer.

In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries.

The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Access This Full Report @ http://www.radiantinsights.com/research/pharmapoint-prophylactic-human-papillomavirus-vaccines-canada-drug-forecast-and-market-analysis-to-2022

The anticipated addition of boys to routine HPV vaccine recommendations by different Canadian provinces is expected to serve as a significant driver to growth within the HPV vaccines market in Canada over the forecast period. In addition, from primary research insight, GlobalData projects Merck's nine-valent vaccine V503 to be widely adopted in the country. This will also significantly enhance the size of the HPV vaccines sector in Canada.

Scope

- Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the Canada including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the Canada from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prophylactic Human Papillomavirus Vaccines disease market.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://radiantinsights.weebly.com/